Natural products are chemical compounds produced by living organisms, and they have shaped modern medicine to a degree that surprises most people. Plants, bacteria, fungi, and marine invertebrates all synthesize molecules with biological activity, many of which became the starting points for drugs now considered essential. From antibiotics and cancer therapies to antimalarials, nature’s chemical toolkit remains one of the richest sources of new drug candidates, even as fully synthetic chemistry has matured.
What Counts as a Natural Product
In scientific usage, “natural product” does not mean the same thing as it does on a grocery label. The term refers to small molecules produced by organisms through specialized metabolic pathways. These are distinct from the primary metabolites every cell needs to survive, like sugars and amino acids. Instead, natural products are secondary metabolites: chemicals that organisms make for specific ecological purposes but that are not strictly required for basic growth or reproduction. Classical chemistry methods have enabled the discovery of a vast range of these bioactive compounds from both land and sea, and many have gone on to become drug candidates.1PubMed Central. A historical overview of natural products in drug discovery
The chemical diversity is staggering. Some organisms produce simple molecules with a single ring structure; others build elaborate architectures with dozens of stereocenters that synthetic chemists struggle to replicate in the lab. Two of the most prolific families of natural products are polyketides and nonribosomal peptides, which are assembled on large enzyme complexes. A comprehensive genomic survey found over 3,300 gene clusters responsible for making these compounds across 991 organisms spanning all three domains of life, with more than 1,100 of those clusters being hybrids that mix both chemical strategies.2PubMed Central. Atlas of nonribosomal peptide and polyketide biosynthetic pathways reveals common occurrence of nonmodular enzymes Polyketide-peptide hybrids are particularly interesting because combining the two chemical toolkits expands what the resulting molecule can do biologically.3PubMed. Protein-protein interactions in polyketide synthase-nonribosomal peptide synthetase hybrid assembly lines
Why Organisms Bother Making Them
Making complex secondary metabolites is expensive. They require dedicated enzymes, consume energy, and divert resources from growth. So why do organisms invest so heavily in producing them? The short answer is survival, but the details are more interesting than a single word suggests.
Plants synthesize secondary metabolites to defend themselves against herbivores. These compounds can be directly toxic to insects, deter feeding through taste or irritation, or even recruit predators of the herbivores by releasing volatile signals. Plant secondary metabolites shape interactions across multiple levels of an ecosystem, involving the plant, the herbivore, the herbivore’s predators, and even pollinators.4PubMed Central. Plant Secondary Metabolites as Defense Tools against Herbivores for Sustainable Crop Protection The variation in these chemicals is enormous, even within a single species. Individual plants of the same species growing in the same area can have measurably different blends of defensive compounds, and that diversity itself has ecological value: it makes it harder for any one pest to evolve a blanket resistance strategy.5PubMed. Explaining intraspecific diversity in plant secondary metabolites in an ecological context
For microbes, the picture involves an arms race played out in soil and on surfaces. Bacteria and fungi produce antibiotics and other bioactive molecules to compete for territory and nutrients. This competition is remarkably sophisticated, and it brings us to one of the most fascinating areas of natural product biology.
Microbial Chemical Warfare
There has been a long-running debate about whether bacteria produce antibiotics as weapons against competitors or as cooperative signals. Research in the genus Streptomyces, which produces an outsized share of clinically used antibiotics, has come down firmly on the weapons side, though with an important twist. Bacteria do not produce antibiotics all the time. Instead, they ramp up production when they sense competitors nearby and, just as shrewdly, try to suppress antibiotic production in their rivals. This saves the cost of constant production while maintaining the ability to fight when it matters.6PubMed Central. Socially mediated induction and suppression of antibiosis during bacterial coexistence
The social dynamics get more complicated. Antibiotic production in Streptomyces is more likely to be triggered by cues from closely related strains or from competitors that share similar biosynthetic gene clusters, rather than by general signals of cell damage. When resources are scarce, antibiotic production actually tends to decline, suggesting that the metabolic cost becomes too high when the organism is already stressed.7PubMed Central. Competition Sensing Changes Antibiotic Production in Streptomyces Computer simulations based on these facultative strategies show that the ability to selectively turn antibiotic production on and off can help maintain biodiversity in microbial communities, converting what would be lethal confrontations into neutral standoffs.8PubMed Central. Socially mediated induction and suppression of antibiosis during bacterial coexistence
Antibiotic self-resistance has its own evolutionary story. When an organism produces a toxic compound, it needs a way to avoid poisoning itself. Research on a class of antibiotics called odilorhabdins, produced by bacteria that live inside insect-killing nematodes, found that the self-resistance gene is exclusively linked to the production gene cluster and has not spread by horizontal gene transfer. The production of the antibiotic and the self-protection mechanism evolved together as ancient features of this particular host-vector-symbiont relationship.9PubMed Central. The Odilorhabdin Antibiotic Biosynthetic Cluster and Acetyltransferase Self-Resistance Locus Are Niche and Species Specific
Landmark Drugs from Nature
Two examples illustrate the remarkable impact natural products have had on modern medicine.
Artemisinin, the antimalarial compound that earned Youyou Tu a Nobel Prize, was discovered by Chinese scientists from the sweet wormwood plant Artemisia annua.10PubMed Central. Discovery, mechanisms of action and combination therapy of artemisinin It works through a mechanism entirely different from older antimalarials, which is why it remains effective against parasites that have become resistant to other treatments. Artemisinin-based combination therapies are now the global standard of care for malaria, a disease that still kills hundreds of thousands of people annually.
Paclitaxel, sold under the brand name Taxol, was originally isolated from the bark of the Pacific yew tree. It works by stabilizing structures inside cells called microtubules, essentially locking the cell’s internal scaffolding in place so it cannot divide. This makes it effective against several cancers, and it is approved for the treatment of ovarian, breast, and lung cancer, as well as Kaposi’s sarcoma.11PubMed Central. How Taxol/paclitaxel kills cancer cells Unlike other antimicrotubule drugs that destabilize these structures, paclitaxel promotes their assembly, making it mechanistically unusual.12Seminars in Oncology Nursing. Overview of Paclitaxel (TAXOL®)
Marine organisms have also contributed heavily. Sponges, which are among the oldest animals on the planet, have been the single best source of marine natural products.13PubMed Central. Marine sponge derived natural products between 2001 and 2010: trends and opportunities for discovery of bioactives One derivative of a sponge-produced compound, eribulin, was approved by the FDA in 2010 for breast cancer and later in 2016 for liposarcoma. Eribulin is notable because it required total chemical synthesis to produce; the natural compound itself was too scarce and too complex to harvest directly. A related analogue showed sub-nanomolar activity against human cancer cell lines in laboratory testing.14PubMed Central. The quest for supernatural products: The impact of total synthesis in complex natural products medicinal chemistry
The Problem of Hidden Chemistry
One of the biggest surprises from the genomics era is how much chemistry microorganisms keep hidden. When researchers sequenced microbial genomes, they found far more biosynthetic gene clusters than the number of compounds those organisms were known to produce. The gap is enormous. Under standard laboratory conditions, most of these gene clusters stay silent, meaning the organism has the genetic blueprint for making compounds that it simply does not make when growing in a flask.15Nature Reviews Microbiology. Discovery of microbial natural products by activation of silent biosynthetic gene clusters
This discovery reshaped the field. Traditional screening involved growing microbes, collecting what they produced, and testing it for biological activity. If a gene cluster was silent, the compound it encoded simply never appeared in the screen. The realization that microbes have been holding back their best chemistry led to an entire subdiscipline focused on “waking up” silent clusters through genetic manipulation, altered growth conditions, or co-culturing with competitor organisms that might trigger production.
The problem also explains why the rate of discovering new antibiotics from soil bacteria slowed in the late twentieth century. Researchers were finding the same compounds repeatedly because they were sampling only the fraction of the chemical repertoire that organisms produce under laboratory conditions. The untapped reservoir is thought to dwarf what has been found so far.
Dereplication and High-Throughput Screening
Rediscovering known compounds wastes time and money, so modern natural product research depends on efficient methods to identify and set aside molecules that have already been characterized. This process, called dereplication, has become a critical step in the re-emergence of natural products as a source of drug leads. Current workflows can rapidly flag known compounds in the early stages of a screening campaign, letting researchers focus their effort on genuinely novel molecules.16PubMed. Natural Products Dereplication: Databases and Analytical Methods
High-throughput screening has also adapted to handle natural product libraries. These approaches allow rapid testing of large collections of molecules for bioactivity, and they hold particular promise for antibacterial drug discovery, where the pipeline has thinned dangerously over the past few decades.17PubMed Central. High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery
Synthetic Biology and Engineered Production
Even when a promising natural product is identified, getting enough of it can be a serious bottleneck. The Pacific yew bark that yielded paclitaxel was a finite resource, and harvesting it threatened the tree. Marine sponges produce compounds in tiny quantities and cannot be farmed at scale. This supply problem has driven researchers toward synthetic biology: transplanting the biosynthetic genes from the source organism into a fast-growing host like yeast or E. coli and engineering it to become a living factory.
Enhanced genome editing tools adapted for natural products research now allow researchers to build combinatorial libraries of compound variants and optimize production levels through high-throughput methods.18PubMed Central. Synthetic Biology of Natural Products In the past two decades, engineered biosynthesis of many plant-derived natural products has been achieved through microbial cell factories, and the host range has expanded from single-celled microbes to complex plant systems as plant genetic modification techniques have improved.19PubMed Central. Synthetic biology of plant natural products: From pathway elucidation to engineered biosynthesis in plant cells The integration of metabolic engineering with rational pathway design is now reshaping how natural products are manufactured, aiming for efficiency and sustainability that wild harvesting cannot match.20Natural Products in Biomedical Research: Frontiers in Medicine. Synthetic Biology and Metabolic Engineering for Natural Product Biosynthesis
Protein engineering of the biosynthetic enzymes themselves, particularly the polyketide synthase and nonribosomal peptide synthetase assembly lines, has been a longstanding target of research. The goal is to swap in different enzyme modules to produce novel analogs of known bioactive compounds, essentially using nature’s machinery to build molecules that nature never made.21PubMed Central. Engineering polyketide synthases and nonribosomal peptide synthetases
Fungi Living Inside Plants
In the early 1990s, researchers made a startling discovery. A fungus called Taxomyces andreanae, isolated from the inner bark of the Pacific yew, could produce paclitaxel and related compounds on its own when grown in a laboratory medium.22PubMed. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew The fungus was an endophyte, an organism that lives inside plant tissues without causing obvious disease. The question of how a fungus came to possess the genetic machinery for making such a complex plant compound remains debated, with some researchers arguing the biosynthetic pathway was acquired from the host plant over evolutionary time.23PubMed Central. Exploiting the Biosynthetic Potency of Taxol from Fungal Endophytes of Conifers Plants; Genome Mining and Metabolic Manipulation
Since that initial finding, fungal endophytes have emerged as a broad source of bioactive natural products. They produce compounds across many chemical classes, including alkaloids, flavonoids, terpenoids, quinones, and others, many of which mimic the pharmacologically valuable products of their host plants.24PubMed Central. Fungal Endophytes as Efficient Sources of Plant-Derived Bioactive Compounds and Their Prospective Applications in Natural Product Drug Discovery: Insights, Avenues, and Challenges The practical appeal is obvious: if you can grow a fungus in a tank to produce the same compound that would otherwise require harvesting a slow-growing tree, the sustainability calculus changes dramatically. In practice, though, many endophyte cultures lose the ability to produce the target compound after several laboratory passages, which remains a significant hurdle.
When Natural Does Not Mean Safe
The word “natural” carries a halo effect in popular culture, but natural products can interact with prescription drugs in dangerous ways. The most thoroughly documented example is St. John’s wort, an herbal supplement widely used for mild depression. One of its active constituents, hyperforin, turns out to be a potent activator of a receptor in the liver that controls the expression of a key drug-metabolizing enzyme. Because that enzyme is involved in breaking down more than half of all prescription medications, the interaction potential is enormous.25PubMed. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor
Clinical observations have confirmed the real-world consequences. Documented interactions include reduced blood levels of the organ-transplant drug cyclosporin, serotonin syndrome when combined with certain antidepressants, unwanted pregnancies in women taking oral contraceptives, and reduced effectiveness of antiretroviral and anticancer medications.26PubMed Central. Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations A pharmacokinetic study found that long-term St. John’s wort use roughly doubled the oral clearance of the sedative midazolam and significantly reduced how much of the drug reached the bloodstream.27PubMed. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity The effect was specific to the liver enzyme pathway involved; other major drug-metabolizing enzymes were not affected.
St. John’s wort is not an outlier so much as the best-studied example of a broader issue. Botanical dietary supplements enter a global supply chain where quality control standards vary. The differing ways that countries recognize pharmacopeial standards, combined with the adoption of traditional medicines as dietary supplement ingredients, creates ongoing challenges for ensuring that what is in the bottle matches what is on the label.28PubMed. Pharmacopeial Standards for the Quality Control of Botanical Dietary Supplements in the United States
Machine Learning Enters the Field
Natural product chemistry generates complex data, and the field has increasingly turned to computational tools to make sense of it. Machine learning algorithms are now being applied across a range of challenges, from predicting the chemical identity and concentration of compounds in crude extracts to classifying new molecules by their likely biological activity.29Chemistry Africa. From 2015 to 2023: How Machine Learning Aids Natural Product Analysis
One area where artificial intelligence is making a tangible difference is in structural elucidation, the process of figuring out the three-dimensional arrangement of atoms in a new compound. Traditionally, this relies on nuclear magnetic resonance spectroscopy, and interpreting the spectra of a novel natural product with many stereocenters can take weeks or months of expert effort. Machine learning models can now predict NMR chemical shifts with high accuracy, rank candidate structures by probability, and reduce the risk of misassignment.30PubMed Central. Nature meets machine: the AI renaissance in natural product drug discovery Recent graph neural network architectures can even distinguish between mirror-image forms of the same molecule, which matter enormously because two mirror-image versions of a compound can have completely different biological effects.31PubMed Central. Nature meets machine: the AI renaissance in natural product drug discovery Computational approaches to NMR prediction and structure correlation are advancing in parallel, further speeding up the bottleneck between isolating a compound and knowing what it is.32Frontiers in Natural Products. Machine learning in computational NMR-aided structural elucidation
Who Owns Knowledge from the Forest
The history of natural product drug discovery is entangled with questions of fairness. Many of the most important leads came from organisms used in traditional medicine by indigenous communities, and the pharmaceutical industry has not always shared the economic benefits equitably. The patenting of herbs and natural products by corporations has been criticized for disregarding the ownership of knowledge held by the communities that first identified these substances as medicinal. Despite numerous court decisions and international treaties from bodies including the United Nations and World Health Organization, a rational system of benefit sharing between producers and indigenous communities remains, by many assessments, a distant reality.33PubMed. Biopiracy of natural products and good bioprospecting practice
The Nagoya Protocol, adopted in 2010, attempted to codify rules for access to genetic resources and fair sharing of the benefits arising from their use. In practice, compliance is uneven, and the legal landscape around bioprospecting remains fragmented. Some countries have responded by restricting access to their biological resources entirely, which has the unintended effect of slowing research. Researchers working in this space increasingly recognize that building collaborative relationships with source communities, rather than treating traditional knowledge as raw material for extraction, is both the ethical and the practical path forward. Whether the frameworks in place are strong enough to make that happen consistently is another question entirely.